New collaboration aims to break barriers in brain‑targeted drug discovery
News
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma
Pepaxti study supports use in wider myeloma population
Phase 2 bridge data show consistent outcomes in patients with impaired kidney function
UCB reports positive outcomes for bimekizumab in psoriatic arthritis
Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic
AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial
Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies
Parsortix platform to support minimally invasive analysis across various cancer trials
Microbiotica reports positive results for MB097 in advanced melanoma
Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment
MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
Belfast base will expand regulatory support, boost innovation and deepen engagement
Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
Responders achieved weight loss and improvements in physical function
Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
Lead candidate ETD001 delivers significant lung function improvement
SMC backs first-line metastatic bladder cancer combination after trial results
Enfortumab vedotin and pembrolizumab recommended for NHS Scotland
Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
Second national grant strengthens company’s expanding global IP estate
